Oncternal Therapeutics Has Been Granted U.S. Patent Number 12,128,026 Titled "Selective Androgen Receptor Degrader Ligands And Methods Of Use Thereof (For The Treatment Of Prostate Cancer)"
Oncternal Therapeutics Has Been Granted U.S. Patent Number 12,128,026 Titled "Selective Androgen Receptor Degrader Ligands And Methods Of Use Thereof (For The Treatment Of Prostate Cancer)"
oncternal therapeutics已獲得美國專利號12,128,026，名稱爲"選擇性雄激素受體降解劑配體及其使用方法（用於治療前列腺癌）"
Oncternal Therapeutics Has Been Granted U.S. Patent Number 12,128,026 Titled "Selective Androgen Receptor Degrader Ligands And Methods Of Use Thereof (For The Treatment Of Prostate Cancer)"
oncternal therapeutics已獲得美國專利號12,128,026，名稱爲"選擇性雄激素受體降解劑配體及其使用方法（用於治療前列腺癌）"
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間